<p>A) Comparison of the conformation of the activation loop and DFG motif in our structure (DFG-Out, yellow) and in the dasatinib cocrystal structure (DFG-In, gray). The sidechains of D381 in the dasatinib structure and F382 in our structure, which occupy very similar positions, are shown as spheres. Bosutinib is shown as sticks and spheres. The position of the phosphate group on the phosphorylated sidechain of Y393 in the dasatinib structure is shown as an orange sphere. B) Binding curves for bosutinib binding to Abl and to Abl phosphorylated on the activation loop (Abl-pY393).</p
A new knowledge, structure, and sequence based strategy involving the effective exploitation of the ...
<p>(A) Grey defines the molecular surface and the cartoon represents the secondary structure of <i>M...
<p>Chemical structures of studied BRAF inhibitors: (A) PLX4720, (B) Vemurafenib (B), PLX7904 (C) and...
<p>A) Interaction of bosutinib (blue) with the hinge region of Abl (yellow). For comparison, the bin...
<p>Conformational dynamics profiles are shown for the crystal structures of Bosutinib complexes with...
<p>The ensemble-based numbers of the intermolecular contacts formed by Dasatinib with the binding si...
<p>Ligand interaction diagram of (A) bosutinib and (B) dasatinib docked into TβR-1. Ligand is repres...
<div><p>Chronic myeloid leukemia (CML) is caused by the kinase activity of the BCR-Abl fusion protei...
<p>Protein is represented by purple carbon cartoon representation with residues surrounding a ligand...
The positions of the P-loop and the activation loop are indicated in yellow. Imatinib binds and stab...
Dasatinib is a second-generation BCR-ABL inhibitor approved for the treatment of patients with chron...
<p>(A) active Lck DFG-in conformation (pdb: 3LCK); (B) active c-Src T338I DFG-in conformation (pdb: ...
<div><p>(A) The kinase domain of Abl (molecule B) is shown as a cartoon with the bisubstrate analog ...
<p>(a–b). The phi backbone torsion angle of D564 in TAE226 bound FAK (a) is rotated by approximately...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
A new knowledge, structure, and sequence based strategy involving the effective exploitation of the ...
<p>(A) Grey defines the molecular surface and the cartoon represents the secondary structure of <i>M...
<p>Chemical structures of studied BRAF inhibitors: (A) PLX4720, (B) Vemurafenib (B), PLX7904 (C) and...
<p>A) Interaction of bosutinib (blue) with the hinge region of Abl (yellow). For comparison, the bin...
<p>Conformational dynamics profiles are shown for the crystal structures of Bosutinib complexes with...
<p>The ensemble-based numbers of the intermolecular contacts formed by Dasatinib with the binding si...
<p>Ligand interaction diagram of (A) bosutinib and (B) dasatinib docked into TβR-1. Ligand is repres...
<div><p>Chronic myeloid leukemia (CML) is caused by the kinase activity of the BCR-Abl fusion protei...
<p>Protein is represented by purple carbon cartoon representation with residues surrounding a ligand...
The positions of the P-loop and the activation loop are indicated in yellow. Imatinib binds and stab...
Dasatinib is a second-generation BCR-ABL inhibitor approved for the treatment of patients with chron...
<p>(A) active Lck DFG-in conformation (pdb: 3LCK); (B) active c-Src T338I DFG-in conformation (pdb: ...
<div><p>(A) The kinase domain of Abl (molecule B) is shown as a cartoon with the bisubstrate analog ...
<p>(a–b). The phi backbone torsion angle of D564 in TAE226 bound FAK (a) is rotated by approximately...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
A new knowledge, structure, and sequence based strategy involving the effective exploitation of the ...
<p>(A) Grey defines the molecular surface and the cartoon represents the secondary structure of <i>M...
<p>Chemical structures of studied BRAF inhibitors: (A) PLX4720, (B) Vemurafenib (B), PLX7904 (C) and...